EMA Authorised: Desloratadine Teva (desloratadine) — Teva B.V

View source ↗

Summary

The EMA authorised Desloratadine Teva (desloratadine) for allergic rhinitis (perennial and seasonal) with Teva B.V. as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• Desloratadine Teva (desloratadine)

Snippet

Status: Authorised. Therapeutic area: Rhinitis, Allergic, Perennial;Rhinitis, Allergic, Seasonal. MAH: Teva B.V. Decision date: 30/05/2022